Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

← catalyst calendar

NCT04624230 · readout in 210 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
118actual
Sites
69
Countries
Australia, Belgium, Canada +13

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-08-12actualWhen the study began enrolling
Primary completion2027-03-17estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2029-06-06estimatedThe whole study's end, after follow-up
First posted2020-11-10actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-03actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Ulcerative Colitis

Intervention

  • Drug: tofacitinib

Primary outcome

what the primary-completion date above is the date OF
Remission by central read Mayo score following 44 weeks in the maintenance phase.
measured Outcome measured at the end of the 44 weeks of the maintenance phase.

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed